

FILE 'REGISTRY' ENTERED AT 12:32:47 ON 07 SEP 2009  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2009 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file  
provided by InfoChem.

STRUCTURE FILE UPDATES: 6 SEP 2009 HIGHEST RN 1180919-38-3  
DICTIONARY FILE UPDATES: 6 SEP 2009 HIGHEST RN 1180919-38-3

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 26, 2009.



Please note that search-term pricing does apply when  
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and  
predicted properties as well as tags indicating availability of  
experimental property data in the original document. For information  
on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=>

Uploading C:\Program Files\STNEXP\Queries\10595882-2.str



chain nodes :  
11 12 13 16  
ring nodes :  
1 2 3 4 5 6 7 8 9 10  
chain bonds :  
3-12 8-11 12-13 13-16  
ring bonds :  
1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-10 7-8 8-9 9-10

exact/norm bonds :  
3-12 5-7 6-10 7-8 8-9 8-11 9-10 12-13 13-16  
normalized bonds :  
1-2 1-6 2-3 3-4 4-5 5-6

G1:C,N

Match level :  
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom  
11:CLASS 12:Atom 13:CLASS 16:Atom

L1        STRUCTURE UPLOADED

=> S l1 sss sam  
SAMPLE SEARCH INITIATED 12:33:37 FILE 'REGISTRY'  
SAMPLE SCREEN SEARCH COMPLETED -        81544 TO ITERATE


2.5% PROCESSED        2000 ITERATIONS        5 ANSWERS  
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)  
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:    ONLINE   \*\*COMPLETE\*\*  
                              BATCH   \*\*COMPLETE\*\*  
PROJECTED ITERATIONS:        1613872 TO 1647888  
PROJECTED ANSWERS:            3221 TO        4933

L2                5 SEA SSS SAM L1


=> D scan

L2    5 ANSWERS    REGISTRY    COPYRIGHT 2009 ACS on STN  
IN    3-Pyridinesulfonamide, N-[4-[1,2-dihydro-7-[(4-methyl-1-  
piperazinyl)carbonyl]-2-oxo-3-quinolinyl]-2-thiazolyl]-N-methyl-  
MF    C24 H24 N6 O4 S2



HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1


L2    5 ANSWERS    REGISTRY    COPYRIGHT 2009 ACS on STN  
IN    2,3-Quinoxalinedione, 1-cyclohexyl-1,4-dihydro-6-nitro-7-[3-[(4-phenyl-1-  
piperazinyl)methyl]-1H-pyrrol-1-yl]-  
MF    C29 H32 N6 O4



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*


HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L2 5 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
 IN 2-Thiophenesulfonamide, N-[4-[1,2-dihydro-7-[(4-methyl-1-piperidinyl)carbonyl]-2-oxo-3-quinolinyl]-2-thiazolyl]-N-methyl-  
 MF C24 H24 N4 O4 S3



HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1


L2 5 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
 IN 2,3-Quinoxalinedione, 6-[amino(2-iodophenyl)methyl]-1,4-dihydro-  
 MF C15 H12 I N3 O2



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L2 5 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
 IN 2-(1H)-Quinoxalinone, 7-[1-(1H-imidazol-1-yl)ethyl]-  
 MF C13 H12 N4 O





\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

ALL ANSWERS HAVE BEEN SCANNED

=>

Uploading C:\Program Files\STNEXP\Queries\10595882-3.str



```

chain nodes :
11 12 13 16 18
ring nodes :
1 2 3 4 5 6 7 8 9 10
chain bonds :
3-12 7-18 8-11 12-13 13-16
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-10 7-8 8-9 9-10
exact/norm bonds :
3-12 5-7 6-10 7-8 7-18 8-9 8-11 9-10 12-13 13-16
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6

```

G1:C,N

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom

11:CLASS 12:Atom 13:CLASS 16:Atom 18:CLASS

L3 STRUCTURE UPLOADED

=> S 13 sss sam

SAMPLE SEARCH INITIATED 12:37:31 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 41839 TO ITERATE

4.8% PROCESSED 2000 ITERATIONS

10 ANSWERS

INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE \*\*COMPLETE\*\*

BATCH \*\*COMPLETE\*\*

PROJECTED ITERATIONS: 824554 TO 849006

PROJECTED ANSWERS: 3316 TO 5050


L4 10 SEA SSS SAM L3

=> D scan

L4 10 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN

IN 2-(1H)-Quinolinone, 7-[(2-methyl-1-piperidiny)carbonyl]-3-[5-[(2-thienylsulfonyl)methyl]-1,2,4-thiadiazol-3-yl]-

MF C23 H22 N4 O4 S3




HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L4 10 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN


IN 2-Thiophenesulfonamide, N-[5-[4-amino-1,2-dihydro-7-[(4-methyl-1-piperidiny)carbonyl]-2-oxo-3-quinolinyl]-1,2,4-thiadiazol-3-yl]-N-methyl-

MF C23 H24 N6 O4 S3



HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1


L4 10 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
IN 2,3-Quinoxalinedione, 6-[amino(2-iodophenyl)methyl]-1,4-dihydro-  
MF C15 H12 I N3 O2



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*


HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L4 10 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
IN INDEX NAME NOT YET ASSIGNED  
MF C27 H31 N5 O3 S2



HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1


L4 10 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
IN 3-Pyridinesulfonamide, N-[5-[4-amino-1,2-dihydro-7-(2-(3-methyl-1-piperidiny)ethyl)-2-oxo-3-quinoliny]]-1,2,4-thiadiazol-3-yl]-N-methyl-  
MF C25 H29 N7 O3 S2



HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1


L4 10 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
IN 3-Pyridinesulfonamide, N-[2-[1,2-dihydro-2-oxo-7-(1-piperidiny)carbonyl]-3-yl]-N-methyl-

quinoliny]]-4-thiazolyl]-N-methyl-  
MF C24 H23 N5 O4 S2




HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L4 10 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
IN 2(1H)-Quinolone, 4-amino-7-[2-(2-methyl-1-piperidinyl)ethyl]-3-[3-(4-  
pyridinyl)-1,2,4-thiadiazol-5-yl]-  
MF C24 H26 N6 O S




HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L4 10 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
IN 2(1H)-Quinolone, 7-[(2-methyl-1-piperidinyl)methyl]-3-[4-(4-pyridinyl)-2-  
thiazolyl]-  
MF C24 H24 N4 O S



HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L4 10 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
IN 4-Pyridinesulfonamide, N-[2-[1,2-dihydro-2-oxo-7-[2-(1-pyrrolidinyl)ethyl]-  
3-quinoliny]]-4-thiazolyl]-N-methyl-  
MF C24 H25 N5 O3 S2




HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L4 10 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN

IN 2(1H)-Quinolinone, 3-[2-[(phenylsulfonyl)methyl]-4-thiazolyl]-7-(1-piperazinylmethyl)-

MF C24 H24 N4 O3 S2





\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

ALL ANSWERS HAVE BEEN SCANNED

=>

Uploading C:\Program Files\STNEXP\Queries\10595882-5.str





chain nodes :  
11 12 13 16 18 19  
ring nodes :  
1 2 3 4 5 6 7 8 9 10  
chain bonds :  
3-12 7-18 8-11 9-19 12-13 13-16  
ring bonds :  
1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-10 7-8 8-9 9-10  
exact/norm bonds :  
3-12 5-7 6-10 7-8 7-18 8-9 8-11 9-10 9-19 12-13 13-16  
normalized bonds :  
1-2 1-6 2-3 3-4 4-5 5-6

G1:C,N

Match level :  
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom  
11:CLASS 12:Atom 13:CLASS 16:Atom 18:CLASS 19:CLASS  
Element Count :  
Node 19: Limited  
C,C1-6

L5 STRUCTURE UPLOADED

=> S 15 sss sam  
SAMPLE SEARCH INITIATED 12:44:01 FILE 'REGISTRY'  
SAMPLE SCREEN SEARCH COMPLETED - 41839 TO ITERATE  
  
4.8% PROCESSED 2000 ITERATIONS 0 ANSWERS  
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)  
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE \*\*COMPLETE\*\*  
BATCH \*\*COMPLETE\*\*  
PROJECTED ITERATIONS: 824554 TO 849006  
PROJECTED ANSWERS: 0 TO 0

L6 0 SEA SSS SAM L5


=> S 15 sss full  
FULL SEARCH INITIATED 12:45:08 FILE 'REGISTRY'  
FULL SCREEN SEARCH COMPLETED - 838410 TO ITERATE  
  
97.3% PROCESSED 816071 ITERATIONS 186 ANSWERS  
  
100.0% PROCESSED 838410 ITERATIONS 186 ANSWERS  
SEARCH TIME: 00.00.21

L7 186 SEA SSS FUL L5

=> D scan

L7 186 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
IN 2(1H)-Quinolinone, 3-ethyl-5-methoxy-7-[[4-(2-methoxyphenyl)-1-piperazinyl]methyl]-


MF C24 H29 N3 O3



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1


L7 186 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
IN 2(1H)-Quinolinone, 3-ethyl-7-[[4-(4-pyridinyl)-1-piperazinyl]methyl]-  
MF C21 H24 N4 O



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L7 186 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
IN 2(1H)-Quinolinone, 3-ethyl-7-[2-hydroxy-1-(4-morpholinyl)ethyl]-  
MF C17 H22 N2 O3



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):end

=> file zcplus  
COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION

FULL ESTIMATED COST

195.96

196.18

FILE 'ZCAPLUS' ENTERED AT 12:46:12 ON 07 SEP 2009  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2009 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS is strictly prohibited.

FILE COVERS 1907 - 7 Sep 2009 VOL 151 ISS 11  
FILE LAST UPDATED: 6 Sep 2009 (20090906/ED)  
REVISED CLASS FIELDS (/NCL) LAST RELOADED: Jun 2009  
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Jun 2009

ZCAplus now includes complete International Patent Classification (IPC) reclassification data for the third quarter of 2009.

CAS Information Use Policies apply and are available at:

<http://www.cas.org/legal/infopolicy.html>

This file contains CAS Registry Numbers for easy and accurate substance identification.

The ALL, BIB, MAX, and STD display formats in the CA/CAplus family of databases have been updated to include new citing references information. This enhancement may impact record import into database management software. For additional information, refer to NEWS 9.

=> d his

(FILE 'HOME' ENTERED AT 12:32:33 ON 07 SEP 2009)

FILE 'REGISTRY' ENTERED AT 12:32:47 ON 07 SEP 2009

L1	STRUCTURE UPLOADED
L2	5 S L1 SSS SAM
L3	STRUCTURE UPLOADED
L4	10 S L3 SSS SAM
L5	STRUCTURE UPLOADED
L6	0 S L5 SSS SAM
L7	186 S L5 SSS FULL

FILE 'ZCAPLUS' ENTERED AT 12:46:12 ON 07 SEP 2009

=> S l7

L8 10 L7

=> D ibib hitstr 10

L8 ANSWER 10 OF 10 ZCAPLUS COPYRIGHT 2009 ACS on STN  
ACCESSION NUMBER: 1990:612014 ZCAPLUS <<LOGINID::20090907>>

DOCUMENT NUMBER: 113:212014  
ORIGINAL REFERENCE NO.: 113:35835a,35838a  
TITLE: Preparation of (1H-azol-1-ylmethyl)quinolines,  
-quinazolines, and -quinoxalines as drugs  
INVENTOR(S): Freyne, Eddy Jean Edgard; Venet, Marc Gaston;  
Raeymaekers, Alfons Herman Margaretha; Sanz, Gerard  
Charles  
PATENT ASSIGNEE(S): Janssen Pharmaceutica N. V., Belg.  
SOURCE: Eur. Pat. Appl., 106 pp.  
CODEN: EPXXDW  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 371564	A2	19900606	EP 1989-203014	19891128
EP 371564	A3	19910529		
EP 371564	B1	19950712		
R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, LU, NL, SE				
US 5028606	A	19910702	US 1989-434957	19891113
US 5037829	A	19910806	US 1989-435120	19891113
CA 2002864	A1	19900529	CA 1989-2002864	19891114
CA 2002864	C	19991116		
DK 8905994	A	19900530	DK 1989-5994	19891128
DK 172748	B1	19990628		
NO 8904734	A	19900530	NO 1989-4734	19891128
NO 174509	B	19940207		
NO 174509	C	19940518		
AU 8945646	A	19900607	AU 1989-45646	19891128
AU 620946	B2	19920227		
HU 52498	A2	19900728	HU 1989-6220	19891128
HU 205106	B	19920330		
ZA 8909076	A	19910731	ZA 1989-9076	19891128
SU 1780536	A3	19921207	SU 1989-4742543	19891128
IL 92486	A	19930708	IL 1989-92486	19891128
ES 2088889	T3	19961001	ES 1989-203014	19891128
FI 101964	B	19980930	FI 1989-5687	19891128
FI 101964	B1	19980930		
CN 1042912	A	19900613	CN 1989-108925	19891129
CN 1033752	C	19970108		
JP 02223579	A	19900905	JP 1989-307793	19891129
JP 2916181	B2	19990705		
US 5151421	A	19920929	US 1991-672298	19910320
US 5185346	A	19930209	US 1991-704746	19910523
US 5268380	A	19931207	US 1992-973871	19921110
US 5441954	A	19950815	US 1993-131817	19931005
CN 1106004	A	19950802	CN 1994-117801	19941102
CN 1036002	C	19971001		
CN 1106005	A	19950802	CN 1994-117802	19941102
CN 1036003	C	19971001		
US 5612354	A	19970318	US 1995-409551	19950323
PRIORITY APPLN. INFO.:				
			GB 1988-27820	A 19881129
			GB 1988-27821	A 19881129
			GB 1988-27822	A 19881129
			US 1989-434205	B2 19891113
			US 1989-434957	A3 19891113
			US 1991-704746	A3 19910523
			US 1992-973871	A3 19921110
			US 1993-131817	A3 19931005

OTHER SOURCE(S): MARPAT 113:212014


IT 130346-19-9P 130346-28-0P 130346-36-0P  
130346-37-1P 130346-38-2P 130346-40-6P  
130346-44-0P 130346-54-2P 130346-57-5P  
130346-60-0P 130346-61-1P 130346-64-4P  
130346-67-7P 130346-70-2P 130346-71-3P  
130346-74-6P 130346-75-7P 130346-78-0P  
130346-80-4P 130346-92-8P 130347-24-9P  
130347-27-2P 130347-29-4P 130347-38-5P  
130347-40-9P 130347-76-1P 130368-35-3P

RL: SPN (Synthetic preparation); PREP (Preparation)

(preparation of, as retinoate metabolism and aromatase inhibitor)


RN 130346-19-9 ZCAPLUS

CN 2(1H)-Quinoxalinone, 7-(1H-imidazol-1-ylmethyl)-3-methyl- (CA INDEX NAME)




RN 130346-28-0 ZCAPLUS

CN 2(1H)-Quinoxalinone, 7-[1-(1H-imidazol-1-yl)-2-methylpropyl]-3-methyl- (CA INDEX NAME)




RN 130346-36-0 ZCAPLUS

CN 2(1H)-Quinoxalinone, 7-[(3-chlorophenyl)-1H-imidazol-1-ylmethyl]-3-methyl- (CA INDEX NAME)




RN 130346-37-1 ZCAPLUS

CN 2(1H)-Quinoxalinone, 7-[1-(1H-imidazol-1-yl)ethyl]-3-methyl- (CA INDEX NAME)



RN 130346-38-2 ZCAPLUS

CN 2(1H)-Quinoxalinone, 7-[(3-fluorophenyl)-1H-imidazol-1-ylmethyl]-3-methyl-  
(CA INDEX NAME)




RN 130346-40-6 ZCAPLUS

CN 2(1H)-Quinoxalinone, 7-[(4-fluorophenyl)-1H-imidazol-1-ylmethyl]-3-methyl-  
, ethanedioate (1:1) (CA INDEX NAME)

CM 1

CRN 130346-39-3

CMF C19 H15 F N4 O



CM 2

CRN 144-62-7


CMF C2 H2 O4




RN 130346-44-0 ZCAPLUS

CN 2-Quinoxalineacetic acid, 3,4-dihydro-6-[(1H-imidazol-1-yl)methyl]-α-


methyl-3-oxo-, ethyl ester (CA INDEX NAME)




RN 130346-54-2 ZCAPLUS  
CN 2(1H)-Quinoxalinone, 7-[(cyclopropyl-1H-imidazol-1-yl)methyl]-3-methyl- (CA INDEX NAME)




RN 130346-57-5 ZCAPLUS  
CN 2(1H)-Quinoxalinone, 7-[1-(1H-imidazol-1-yl)-2-methylpropyl]-3-(2-methylpropyl)- (CA INDEX NAME)




RN 130346-60-0 ZCAPLUS  
CN 2(1H)-Quinoxalinone, 7-[1-(1H-imidazol-1-yl)-3-methylbutyl]-3-methyl- (CA INDEX NAME)




RN 130346-61-1 ZCAPLUS  
CN 2(1H)-Quinoxalinone, 7-[1-(1H-imidazol-1-yl)-2-methylpropyl]-3-(1-methylethyl)- (CA INDEX NAME)




RN 130346-64-4 ZCAPLUS  
 CN 2(1H)-Quinoxalinone, 7-[1-(1H-imidazol-1-yl)propyl]-3-methyl- (CA INDEX NAME)



RN 130346-67-7 ZCAPLUS  
 CN 2(1H)-Quinoxalinone, 7-[1-(4-chlorophenyl)-1H-imidazol-1-ylmethyl]-3-methyl- (CA INDEX NAME)




RN 130346-70-2 ZCAPLUS  
 CN 2(1H)-Quinoxalinone, 3-ethyl-7-[1-(1H-imidazol-1-yl)phenylmethyl]- (CA INDEX NAME)




RN 130346-71-3 ZCAPLUS  
 CN 2-Quinoxalinecarboxylic acid, 3,4-dihydro-6-[1-(1H-imidazol-1-yl)-2-methylpropyl]-3-oxo-, ethyl ester (CA INDEX NAME)







RN 130346-74-6 ZCAPLUS  
 CN 2(1H)-Quinoxalinone, 7-[1H-imidazol-1-yl(4-methylphenyl)methyl]-3-methyl-  
 (CA INDEX NAME)




RN 130346-75-7 ZCAPLUS  
 CN 2(1H)-Quinoxalinone, 7-[1-(1H-imidazol-1-yl)pentyl]-3-methyl- (CA INDEX  
 NAME)



RN 130346-78-0 ZCAPLUS  
 CN 2(1H)-Quinoxalinone, 7-[1-(1H-imidazol-1-yl)(4-methoxyphenyl)methyl]-3-methyl-  
 (CA INDEX NAME)




RN 130346-80-4 ZCAPLUS  
 CN 2(1H)-Quinoxalinone, 7-[1-(1H-imidazol-1-yl)-2-thienylmethyl]-3-methyl- (CA  
 INDEX NAME)




RN 130346-92-8 ZCAPLUS

CN 2(1H)-Quinoxalinone, 7-[1-(1H-imidazol-1-yl)-2-methylpropyl]-3-propyl-  
(CA INDEX NAME)




RN 130347-24-9 ZCAPLUS

CN 2(1H)-Quinoxalinone, 7-[1H-imidazol-1-yl[4-(1-methylethyl)phenyl]methyl]-3-methyl-  
(CA INDEX NAME)




RN 130347-27-2 ZCAPLUS

CN 2(1H)-Quinoxalinone, 7-[(3-chlorophenyl)-1H-imidazol-1-ylmethyl]-3-(2-methylpropyl)-  
(CA INDEX NAME)




RN 130347-29-4 ZCAPLUS

CN 2(1H)-Quinoxalinone, 7-[1-(3-chlorophenyl)-1H-imidazol-1-ylmethyl]-3-propyl-  
(CA INDEX NAME)




RN 130347-38-5 ZCAPLUS

CN 2(1H)-Quinoxalinone, 7-[(4-chlorophenyl)-1H-imidazol-1-ylmethyl]-3-propyl-  
(CA INDEX NAME)




RN 130347-40-9 ZCAPLUS

CN 2(1H)-Quinoxalinone, 7-[(4-chlorophenyl)-1H-imidazol-1-ylmethyl]-3-(1-methylpropyl)- (CA INDEX NAME)



RN 130347-76-1 ZCAPLUS


CN 2(1H)-Quinoxalinone, 7-[2-methyl-1-(1H-1,2,4-triazol-1-yl)propyl]-3-propyl-  
(CA INDEX NAME)



RN 130368-35-3 ZCAPLUS

CN 2(1H)-Quinoxalinone, 3-methyl-7-[2-methyl-1-(1H-1,2,4-triazol-1-yl)propyl]-

(CA INDEX NAME)



OS.CITING REF COUNT: 24 THERE ARE 24 CAPLUS RECORDS THAT CITE THIS  
RECORD (43 CITINGS)

=> D ibib hitstr 1-9

L8 ANSWER 1 OF 10 ZCAPLUS COPYRIGHT 2009 ACS on STN  
ACCESSION NUMBER: 2009:885718 ZCAPLUS <<LOGINID::20090907>>  
DOCUMENT NUMBER: 151:173496  
TITLE: Fused heterocyclic derivatives as HGF modulators and  
their preparation and methods of use  
INVENTOR(S): Albrecht, Brian K.; Bauer, David; Bellon, Steven;  
Bode, Christiane M.; Booker, Shon; Boezio, Alessandro;  
Choquette, Deborah; D'Amico, Erin; Harmange,  
Jean-Christophe; Hirai, Satoko; Hungate, Randall W.;  
Kim, Tae-Seong; Lewis, Richard T.; Liu, Longbin;  
Lohman, Julia; Norman, Mark H.; Potashman, Michelle;  
Siegmond, Aaron C.; Springer, Stephanie; Stec,  
Markian; Xi, Ning; Yang, Kevin; Peterson, Emily A.;  
Romero, Karina; Copeland, Katrina W.  
PATENT ASSIGNEE(S): Amgen Inc., USA  
SOURCE: PCT Int. Appl., 236pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 3  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2009091374	A2	20090723	WO 2008-US11724	20081014
W:	AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
US 20090124609	A1	20090514	US 2008-9123	20080115
PRIORITY APPLN. INFO.:			US 2008-9123	A2 20080115
			US 2006-830882P	P 20060714
			US 2007-879034	A2 20070713


OTHER SOURCE(S): MARPAT 151:173496  
IT 1151800-61-IP

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU  
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES  
(Uses)

(preparation of fused heterocyclic derivs. as HGF modulators useful in the  
treatment of diseases)

RN 1151800-61-1 ZCAPLUS

CN 2(1H)-Quinoxalinone, 3-methyl-7-[(6-phenyl-1,2,4-triazolo[4,3-b]pyridazin-  
3-yl)methyl]- (CA INDEX NAME)



L8 ANSWER 2 OF 10 ZCAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2009:588488 ZCAPLUS <LOGINID::20090907>

DOCUMENT NUMBER: 150:539755

TITLE: Fused heterocyclic derivatives as HGF modulators and  
their preparation and methods of use

INVENTOR(S): Albrecht, Brian K.; Bauer, David; Bellon, Steven;  
Bode, Christiane M.; Booker, Shon; Boezio, Alessandro;  
Choquette, Deborah; D'Amico, Derin; Harmange,  
Jean-Christophe; Hirai, Satoko; Hungate, Randall W.;  
Kim, Tae-Seong; Lewis, Richard T.; Liu, Longbin;  
Lohman, Julia; Norman, Mark H.; Potashman, Michele;  
Siegmond, Aaron C.; Springer, Stephanie; Stec,  
Markian; Xi, Ning; Yang, Kevin

PATENT ASSIGNEE(S): Amgen Inc., USA

SOURCE: U.S. Pat. Appl. Publ., 252pp., Cont.-in-part of U.S.  
Ser. No. 879,034.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 3


PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20090124609	A1	20090514	US 2008-9123	20080115
US 20090124612	A1	20090514	US 2007-879034	20070713
WO 2009091374	A2	20090723	WO 2008-US11724	20081014
W:	AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
RW:	AE, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			

PRIORITY APPLN. INFO.: US 2006-830882P P 20060714

US 2007-879034 A2 20070713  
US 2008-9123 A2 20080115

OTHER SOURCE(S): MARPAT 150:539755  
IT 1151800-61-1P  
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU  
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES  
(Uses)  
(preparation of fused heterocyclic derivs. as HGF modulators useful in the  
treatment of diseases)  
RN 1151800-61-1 ZCAPLUS  
CN 2(1H)-Quinoxalinone, 3-methyl-7-[(6-phenyl-1,2,4-triazolo[4,3-b]pyridazin-  
3-yl)methyl]- (CA INDEX NAME)



L8 ANSWER 3 OF 10 ZCAPLUS COPYRIGHT 2009 ACS on STN  
ACCESSION NUMBER: 2009:519324 ZCAPLUS <<LOGINID::20090907>>  
DOCUMENT NUMBER: 150:472754  
TITLE: Quinolinone derivatives as PARP-1 inhibitors and their  
preparation, pharmaceutical compositions and use in  
the treatment of diseases  
INVENTOR(S): Angibaud, Patrick Rene; Marconnet-Decrane, Laurence  
Francoise Bernadette; Vialard, Jorge Eduardo;  
Mevellec, Laurence Anne; Meyer, Christophe; Storck,  
Pierre-Henri  
PATENT ASSIGNEE(S): Janssen Pharmaceutica NV, Belg.  
SOURCE: PCT Int. Appl., 103pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2009053373	A1	20090430	WO 2008-EP64243	20081022
W:	AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			

PRIORITY APPLN. INFO.: EP 2007-119417 A 20071026  
OTHER SOURCE(S): MARPAT 150:472754  
IT 1146679-86-8P 1146679-87-9P


RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(drug candidate and intermediate; preparation of quinolinone derivs. as

PARP1 inhibitors useful in the treatment of PARP-mediated diseases)


RN 1146679-86-8 ZCAPLUS

CN 5-Pyrimidinecarboxylic acid, 2-[4-[(3-ethyl-1,2-dihydro-2-oxo-7-quinoliny)methyl]-1-piperazinyl]-, ethyl ester (CA INDEX NAME)



RN 1146679-87-9 ZCAPLUS

CN 5-Pyrimidinecarboxylic acid, 2-[4-[(3-ethyl-1,2-dihydro-2-oxo-7-quinoliny)methyl]-1-piperazinyl]-, hydrochloride (19:12) (CA INDEX NAME)



●12/19 HCl


IT	1146679-77-7P	1146679-78-8P	1146679-80-2P
	1146679-81-3P	1146679-82-4P	1146679-83-5P
	1146679-84-6P	1146679-85-7P	1146679-88-0P
	1146679-91-5P	1146679-92-6P	1146679-93-7P
	1146679-95-9P	1146679-96-0P	1146679-97-1P
	1146679-98-2P	1146680-01-4P	1146680-02-5P
	1146680-03-6P	1146680-04-7P	1146680-05-8P
	1146680-06-9P	1146680-08-1P	1146680-10-5P
	1146680-11-6P	1146680-12-7P	1146680-14-9P
	1146680-15-0P	1146680-16-1P	1146680-17-2P
	1146680-19-4P	1146680-21-8P	1146680-27-4P
	1146680-28-5P	1146680-29-6P	1146680-30-9P
	1146680-31-0P	1146680-32-1P	1146680-33-2P
	1146680-34-3P	1146680-35-4P	1146680-36-5P
	1146680-37-6P	1146680-38-7P	1146680-39-8P
	1146680-40-1P	1146680-41-2P	1146680-42-3P
	1146680-43-4P	1146680-44-5P	1146680-46-7P
	1146680-47-8P	1146680-48-9P	1146680-49-0P
	1146680-50-3P	1146680-51-4P	1146680-52-5P
	1146680-53-6P	1146680-54-7P	1146680-55-8P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of quinolinone derivs. as PARP1 inhibitors useful in the treatment of PARP-mediated diseases)


RN 1146679-77-7 ZCAPLUS

CN 2(1H)-Quinolinone, 3-ethyl-7-[[4-(2-pyridinyl)-1-piperazinyl]methyl]- (CA INDEX NAME)




RN 1146679-78-8 ZCAPLUS

CN 2(1H)-Quinolinone, 3-ethyl-7-[(4-phenyl-1-piperidinyl)methyl]- (CA INDEX NAME)




RN 1146679-80-2 ZCAPLUS

CN 2(1H)-Quinolinone, 3-ethyl-7-[2-hydroxy-1-(4-morpholinyl)ethyl]- (CA INDEX NAME)



RN 1146679-81-3 ZCAPLUS


CN 2(1H)-Quinolinone, 3-ethyl-7-[(4-phenyl-1-piperazinyl)methyl]- (CA INDEX NAME)



RN 1146679-82-4 ZCAPLUS


CN 2(1H)-Quinolinone, 3-methyl-7-[(4-phenyl-1-piperidinyl)methyl]- (CA INDEX NAME)





RN 1146679-83-5 ZCAPLUS


CN 3-Pyridinecarbonitrile, 6-[4-[3-(3-ethyl-1,2-dihydro-2-oxo-7-quinolinyl)propyl]-1-piperazinyl]-, hydrochloride (20:13) (CA INDEX NAME)



●13/20 HCl


RN 1146679-84-6 ZCAPLUS

CN 2(1H)-Quinolinone, 3-ethyl-7-[2-hydroxy-1-[4-(phenylmethyl)-1-piperidinyl]ethyl]- (CA INDEX NAME)




RN 1146679-85-7 ZCAPLUS

CN 2(1H)-Quinolinone, 7-[(3,4-dihydro-2(1H)-isoquinolinyl)carbonyl]-3-ethyl- (CA INDEX NAME)




RN 1146679-88-0 ZCAPLUS

CN 3-Pyridinecarbonitrile, 6-[4-[1-(3-ethyl-1,2-dihydro-2-oxo-7-quinolinyl)-2-methylpropyl]-1-piperazinyl]- (CA INDEX NAME)




RN 1146679-91-5 ZCAPLUS

CN 5-Pyrimidinecarboxamide, 2-[4-[(3-ethyl-1,2-dihydro-2-oxo-7-quinolinyl)methyl]-1-piperazinyl]- (CA INDEX NAME)




RN 1146679-92-6 ZCAPLUS

CN 3-Pyridinecarbonitrile, 6-[4-[(3-ethyl-1,2-dihydro-2-oxo-7-quinolinyl)methyl]-1-piperazinyl]- (CA INDEX NAME)




RN 1146679-93-7 ZCAPLUS

CN 2(1H)-Quinolinone, 7-[4-[(2-chlorophenyl)-1-piperazinyl)methyl]-3-ethyl- (CA INDEX NAME)




RN 1146679-95-9 ZCAPLUS

CN Benzonitrile, 2-[4-[1-(1,2-dihydro-3-methyl-2-oxo-7-quinolinyl)ethyl]-1-piperazinyl]- (CA INDEX NAME)




RN 1146679-96-0 ZCAPLUS

CN 2(1H)-Quinolinone, 7-[(3,6-dihydro-4-phenyl-1(2H)-pyridinyl)methyl]-3-ethyl- (CA INDEX NAME)




RN 1146679-97-1 ZCAPLUS

CN 2(1H)-Quinolinone, 3-ethyl-7-[[4-[5-(trifluoromethyl)-2-pyridinyl]-1-piperazinyl]methyl]- (CA INDEX NAME)




RN 1146679-98-2 ZCAPLUS

CN 2(1H)-Quinolinone, 7-[[4-(2-methoxyphenyl)-1-piperazinyl]methyl]-3-methyl- (CA INDEX NAME)




RN 1146680-01-4 ZCAPLUS

CN 2(1H)-Quinolinone, 3-methyl-7-[[4-(2-pyrimidinyl)-1-piperazinyl]methyl]- (CA INDEX NAME)



RN 1146680-02-5 ZCAPLUS


CN 2(1H)-Quinolinsonone, 3-ethyl-7-[[4-(2-methoxyethyl)-1-piperazinyl]methyl]-  
(CA INDEX NAME)



RN 1146680-03-6 ZCAPLUS


CN 2(1H)-Quinolinsonone, 7-[[{(1S,4S)-5-(4-chlorophenyl)-2,5-diazabicyclo[2.2.1]hept-2-yl]methyl]-3-ethyl- (CA INDEX NAME)

Absolute stereochemistry.




RN 1146680-04-7 ZCAPLUS

CN 2(1H)-Quinolinsonone, 7-[(3,4-dihydro-2(1H)-isoquinolinyl)methyl]-3-ethyl-  
(CA INDEX NAME)



RN 1146680-05-8 ZCAPLUS


CN 2(1H)-Quinolinsonone, 3-ethyl-7-[[4-(2-pyrimidinyl)-1-piperazinyl]methyl]-  
(CA INDEX NAME)



RN 1146680-06-9 ZCAPLUS


CN 2(1H)-Quinolinsonone, 3-ethyl-7-[[4-(phenylmethyl)-1-piperidinyl]methyl]-

(CA INDEX NAME)




RN 1146680-08-1 ZCAPLUS

CN 2(1H)-Quinolinone, 3-ethyl-7-[2-hydroxy-1-[4-(2-pyrimidinyl)-1-piperazinyl]ethyl]- (CA INDEX NAME)




RN 1146680-10-5 ZCAPLUS

CN 2(1H)-Quinolinone, 3-ethyl-7-[[4-(4-pyridinyl)-1-piperazinyl]methyl]- (CA INDEX NAME)




RN 1146680-11-6 ZCAPLUS

CN 2(1H)-Quinolinone, 3-ethyl-7-[[4-(2-pyrazinyl)-1-piperazinyl]methyl]- (CA INDEX NAME)




RN 1146680-12-7 ZCAPLUS


CN 2(1H)-Quinolinone, 3-ethyl-7-[[4-(1H-indazol-3-yl)-1-piperazinyl]methyl]- (CA INDEX NAME)




RN 1146680-14-9 ZCAPLUS  
 CN 2(1H)-Quinolinone, 7-[[4-(3,4-dimethoxyphenyl)-1-piperazinyl]methyl]-3-ethyl- (CA INDEX NAME)




RN 1146680-15-0 ZCAPLUS  
 CN 2(1H)-Quinolinone, 7-[[4-(3,4-dimethylphenyl)-1-piperazinyl]methyl]-3-ethyl- (CA INDEX NAME)



RN 1146680-16-1 ZCAPLUS  
 CN 2(1H)-Quinolinone, 3-ethyl-7-[[4-(4-methoxyphenyl)-1-piperazinyl]methyl]- (CA INDEX NAME)




RN 1146680-17-2 ZCAPLUS  
 CN 2(1H)-Quinolinone, 7-[[4-(3,4-dichlorophenyl)-1-piperazinyl]methyl]-3-ethyl- (CA INDEX NAME)




RN 1146680-19-4 ZCAPLUS

CN 2(1H)-Quinolinone, 3-ethyl-7-[[4-(2-phenylethyl)-1-piperazinyl]methyl]-  
(CA INDEX NAME)




RN 1146680-21-8 ZCAPLUS

CN 2(1H)-Quinolinone, 7-[[4-(3-chlorophenyl)-1-piperazinyl]methyl]-3-ethyl-  
(CA INDEX NAME)




RN 1146680-27-4 ZCAPLUS

CN 2(1H)-Quinolinone, 7-[1-[4-(4-chlorophenyl)-1-piperidinyl]ethyl]-3-methyl-  
(CA INDEX NAME)




RN 1146680-28-5 ZCAPLUS

CN 2(1H)-Quinolinone, 7-[1-(3,6-dihydro-4-phenyl-1(2H)-pyridinyl)ethyl]-3-methyl-  
(CA INDEX NAME)




RN 1146680-29-6 ZCAPLUS

CN 2(1H)-Quinolinone, 7-[1-[4-(2,4-difluorophenyl)-1-piperazinyl]ethyl]-3-methyl-  
(CA INDEX NAME)




RN 1146680-30-9 ZCAPLUS

CN 2(1H)-Quinolinone, 3-methyl-7-[1-(1-piperidinyl)ethyl]- (CA INDEX NAME)




RN 1146680-31-0 ZCAPLUS

CN 2(1H)-Quinolinone, 7-[1-(4-cyclohexyl-1-piperazinyl)ethyl]-3-methyl- (CA INDEX NAME)



RN 1146680-32-1 ZCAPLUS


CN 2(1H)-Quinolinone, 7-[1-[4-[(2-methoxyethyl)amino]-1-piperidinyl]ethyl]-3-methyl- (CA INDEX NAME)



RN 1146680-33-2 ZCAPLUS


CN 2(1H)-Quinolinone, 3-methyl-7-[1-[4-[3-(trifluoromethyl)-2-pyridinyl]-1-piperazinyl]ethyl]- (CA INDEX NAME)






RN 1146680-34-3 ZCAPLUS

CN 2(1H)-Quinolinone, 3-methyl-7-[[4-(2-pyridinyl)-1-piperazinyl]methyl]-  
(CA INDEX NAME)




RN 1146680-35-4 ZCAPLUS

CN 2(1H)-Quinolinone, 7-[1-[4-(3-chlorophenyl)-1-piperazinyl]ethyl]-3-methyl-  
(CA INDEX NAME)




RN 1146680-36-5 ZCAPLUS

CN 2(1H)-Quinolinone, 7-[(3,6-dihydro-4-phenyl-1(2H)-pyridinyl)carbonyl]-3-methyl-  
(CA INDEX NAME)




RN 1146680-37-6 ZCAPLUS

CN 2(1H)-Quinolinone, 7-[[4-(2-chlorophenyl)-1-piperazinyl]carbonyl]-3-methyl-  
(CA INDEX NAME)




RN 1146680-38-7 ZCAPLUS

CN 2(1H)-Quinolinone, 3-ethyl-7-(1-pyrrolidinylmethyl)- (CA INDEX NAME)




RN 1146680-39-8 ZCAPLUS

CN 5-Pyrimidinecarboxamide, 2-[4-[(3-ethyl-1,2-dihydro-2-oxo-7-quinoliny)methyl]-1-piperazinyl]-N-(2-hydroxyethyl)- (CA INDEX NAME)




RN 1146680-40-1 ZCAPLUS

CN 2(1H)-Quinolinone, 7-[(1,3-dihydro-2H-isindol-2-yl)methyl]-3-ethyl- (CA INDEX NAME)




RN 1146680-41-2 ZCAPLUS

CN 2(1H)-Quinolinone, 3-ethyl-5-methoxy-7-[[4-(2-methoxyphenyl)-1-piperazinyl]methyl]- (CA INDEX NAME)




RN 1146680-42-3 ZCAPLUS

CN 2(1H)-Quinolinone, 7-[cyclohexyl(4-phenyl-1-piperidinyl)methyl]-3-methyl-  
(CA INDEX NAME)




RN 1146680-43-4 ZCAPLUS

CN 3-Pyridinecarbonitrile, 6-[4-[1-(1,2-dihydro-3-methyl-2-oxo-7-quinolinyl)-  
2-methylpropyl]-1-piperazinyl]- (CA INDEX NAME)




RN 1146680-44-5 ZCAPLUS

CN Benzonitrile, 2-[4-(cyclohexyl(1,2-dihydro-3-methyl-2-oxo-7-  
quinolinyl)methyl)-1-piperazinyl]- (CA INDEX NAME)




RN 1146680-46-7 ZCAPLUS

CN 2(1H)-Quinolinone, 3-methyl-7-[1-(1-pyrrolidinyl)ethyl]- (CA INDEX NAME)




RN 1146680-47-8 ZCAPLUS

CN 3-Pyridinecarbonitrile, 6-[4-[3-ethyl-1,2-dihydro-5-methoxy-2-oxo-7-  
quinolinyl)methyl]-1-piperazinyl]- (CA INDEX NAME)




RN 1146680-48-9 ZCAPLUS

CN 3-Pyridinecarbonitrile, 6-[4-(cyclohexyl(1,2-dihydro-3-methyl-2-oxo-7-quinolinyl)methyl)-1-piperazinyl]- (CA INDEX NAME)




RN 1146680-49-0 ZCAPLUS

CN 2(1H)-Quinolinone, 7-[[4-(2-chlorophenyl)-1-piperazinyl]methyl]-3-ethyl-5-methoxy- (CA INDEX NAME)




RN 1146680-50-3 ZCAPLUS

CN 2(1H)-Quinolinone, 7-[cyclohexyl[4-(2-methoxyphenyl)-1-piperazinyl]methyl]-3-methyl- (CA INDEX NAME)




RN 1146680-51-4 ZCAPLUS


CN 2(1H)-Quinolinone, 7-[cyclohexyl(3,6-dihydro-4-phenyl-1(2H)-pyridinyl)methyl]-3-methyl- (CA INDEX NAME)




RN 1146680-52-5 ZCAPLUS  
 CN 2(1H)-Quinolinone, 3-methyl-7-[1-(4-phenyl-1-piperidinyl)ethyl]- (CA INDEX NAME)




RN 1146680-53-6 ZCAPLUS  
 CN 2(1H)-Quinolinone, 7-[cyclohexyl[4-(2-pyridinyl)-1-piperazinyl]methyl]-3-methyl- (CA INDEX NAME)




RN 1146680-54-7 ZCAPLUS  
 CN 2(1H)-Quinolinone, 7-[1-[4-(2-chlorophenyl)-1-piperazinyl]ethyl]-3-methyl- (CA INDEX NAME)



RN 1146680-55-8 ZCAPLUS  
 CN 2(1H)-Quinolinone, 7-[[4-(2-chlorophenyl)-1-piperazinyl]cyclohexylmethyl]-3-methyl- (CA INDEX NAME)




IT 1146680-78-5P 1146680-88-7P  
 RL: PRPH (Prophetic); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
 (prophetic intermediate; preparation of quinolinone derivs. as PARP1 inhibitors useful in the treatment of PARP-mediated diseases)  
 RN 1146680-78-5 ZCAPLUS  
 CN 5-Pyrimidinecarbonyl chloride, 2-[4-[(3-ethyl-1,2-dihydro-2-oxo-7-quinolinyl)methyl]-1-piperazinyl]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl


RN 1146680-88-7 ZCAPLUS  
 CN 2(1H)-Quinolinone, 7-(chlorocyclohexylmethyl)-3-methyl- (CA INDEX NAME)



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 4 OF 10 ZCAPLUS COPYRIGHT 2009 ACS on STN  
 ACCESSION NUMBER: 2009:247530 ZCAPLUS <<LOGINID::20090907>>  
 DOCUMENT NUMBER: 150:438012  
 TITLE: Virtual screening for Raf-1 kinase inhibitors based on pharmacophore model of substituted ureas  
 AUTHOR(S): Li, Hui-Fang; Lu, Tao; Zhu, Tian; Jiang, Yong-Jun; Rao, Sha-Sha; Hu, Li-Ye; Xin, Bo-Tao; Chen, Ya-Dong  
 CORPORATE SOURCE: Department of Organic Chemistry, China Pharmaceutical University, Nanjing, 210009, Peop. Rep. China  
 SOURCE: European Journal of Medicinal Chemistry (2009), 44(3), 1240-1249

PUBLISHER: Elsevier Masson SAS  
 DOCUMENT TYPE: Journal  
 LANGUAGE: English  
 IT 883829-01-4, NCI 0648594  
 RL: DMA (Drug mechanism of action); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (virtual screening for Raf-1 kinase inhibitors based on pharmacophore model of substituted ureas)  
 RN 883829-01-4 ZCAPLUS  
 CN 2-Quinoxalinepropanamide, 6-benzoyl-3,4-dihydro-N-(4-methoxy-2-nitrophenyl)- $\alpha$ ,3-dioxo- (CA INDEX NAME)



REFERENCE COUNT: 35 THERE ARE 35 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 5 OF 10 ZCAPLUS COPYRIGHT 2009 ACS on STN  
 ACCESSION NUMBER: 2008:1101739 ZCAPLUS <<LOGINID::20090907>>  
 DOCUMENT NUMBER: 149:355743  
 TITLE: Quinolinone derivatives as PARP and TANK inhibitors and their preparation, pharmaceutical compositions and use in the treatment of diseases  
 INVENTOR(S): Vialard, Jorge Eduardo; Angibaud, Patrick Rene; Mevellec, Laurence Anne; Meyer, Christophe; Freyne, Eddy Jean Edgard; Pilatte, Isabelle Noelle Constance; Roux, Bruno; Pasquier, Elisabeth Therese Jeanne; Bourdrez, Xavier Marc; Adelinet, Christophe Denis; Marconnet-Decrane, Laurence Francoise Bernadette; Macritchie, Jacqueline Anne; Duffy, James Edward Stewart; Owens, Andrew Pate; Storck, Pierre-Henri; Poncelet, Virginie Sophie  
 PATENT ASSIGNEE(S): Janssen Pharmaceutica NV, Belg.  
 SOURCE: PCI Int. Appl., 223pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2008107478	A1	20080912	WO 2008-EP52764	20080307
W:	AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU,  
 IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK,  
 TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD,  
 TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW,  
 AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRIORITY APPLN. INFO.: EP 2007-103788 A 20070308  
 US 2007-893680P P 20070308


OTHER SOURCE(S): MARPAT 149:355743

IT 1056889-05-4P  
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)  
 (drug candidate and intermediate; preparation of quinoline derivs. as PARP and TANK inhibitors useful in the treatment of diseases)  
 RN 1056889-05-4 ZCAPLUS  
 CN 7-Quinolineacetonitrile,  $\alpha$ -(6-bromo-2,3-dihydro-1H-inden-1-yl)-1,2-dihydro- $\alpha$ ,3-dimethyl-2-oxo- (CA INDEX NAME)



IT 1056888-99-3P 1056889-00-9P 1056889-01-0P  
 1056889-02-1P 1056889-03-2P 1056889-04-3P  
 1056889-06-5P 1056890-39-1P 1056891-80-5P  
 1056891-81-6P 1056891-82-7P 1056891-83-8P  
 1056891-84-9P 1056891-85-0P 1056891-86-1P  
 1056891-87-2P 1056891-88-3P 1056891-89-4P  
 1056891-90-7P 1056891-91-8P 1056891-93-0P  
 1056891-94-1P 1056891-95-2P 1056891-99-6P  
 1056892-00-2P 1056892-01-3P 1056892-05-7P  
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (drug candidate; preparation of quinoline derivs. as PARP and TANK inhibitors useful in the treatment of diseases)  
 RN 1056888-99-3 ZCAPLUS  
 CN 7-Quinolineacetonitrile,  $\alpha$ -[(1R)-5-bromo-2,3-dihydro-1H-inden-1-yl]-1,2-dihydro- $\alpha$ ,3-dimethyl-2-oxo-, ( $\alpha$ S)-rel- (CA INDEX NAME)

Relative stereochemistry.




RN 1056889-00-9 ZCAPLUS  
 CN 7-Quinolineacetonitrile,  $\alpha$ -[(1R)-5-bromo-2,3-dihydro-1H-inden-1-yl]-



1,2-dihydro- $\alpha$ ,3-dimethyl-2-oxo-, ( $\alpha$ R)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 1056889-01-0 ZCAPLUS

CN 7-Quinolineacetone nitrile,  $\alpha$ -[(1R)-5-cyano-2,3-dihydro-1H-inden-1-yl]-1,2-dihydro- $\alpha$ ,3-dimethyl-2-oxo-, ( $\alpha$ R)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 1056889-02-1 ZCAPLUS

CN 7-Quinolineacetone nitrile,  $\alpha$ -[(7R)-4-chloro-6,7-dihydro-5H-cyclopenta[b]pyridin-7-yl]-3-ethyl-1,2-dihydro- $\alpha$ -methyl-2-oxo-, ( $\alpha$ S)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 1056889-03-2 ZCAPLUS


CN 7-Quinolineacetone nitrile,  $\alpha$ -[(7R)-4-chloro-6,7-dihydro-5H-cyclopenta[b]pyridin-7-yl]-3-ethyl-1,2-dihydro- $\alpha$ -methyl-2-oxo-, ( $\alpha$ R)-rel- (CA INDEX NAME)

Relative stereochemistry.




RN 1056889-04-3 ZCAPLUS

CN 7-Quinolineacetonitrile,  $\alpha$ -(4-bromo-2,3-dihydro-1H-inden-1-yl)-1,2-dihydro- $\alpha$ ,3-dimethyl-2-oxo- (CA INDEX NAME)




RN 1056889-06-5 ZCAPLUS

CN 7-Quinolineacetonitrile,  $\alpha$ -(6-cyano-2,3-dihydro-1H-inden-1-yl)-1,2-dihydro- $\alpha$ ,3-dimethyl-2-oxo- (CA INDEX NAME)



RN 1056890-39-1 ZCAPLUS

CN 7-Quinolineacetonitrile,  $\alpha$ -cyclopropyl-3-ethyl-1,2-dihydro-2-oxo- $\alpha$ -(2-phenoxyethyl)- (CA INDEX NAME)




RN 1056891-80-5 ZCAPLUS

CN 7-Quinolineacetonitrile,  $\alpha$ -[(1R)-6-bromo-2,3-dihydro-1H-inden-1-yl]-3-ethyl-1,2-dihydro- $\alpha$ -methyl-2-oxo-, (aS)-rel- (CA INDEX)

NAME)


Relative stereochemistry.



RN 1056891-81-6 ZCAPLUS

CN 7-Quinolineacetone nitrile,  $\alpha$ -[(1R)-6-bromo-2,3-dihydro-1H-inden-1-yl]-3-ethyl-1,2-dihydro- $\alpha$ -methyl-2-oxo-, ( $\alpha$ R)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 1056891-82-7 ZCAPLUS

CN 7-Quinolineacetone nitrile, 1,2-dihydro- $\alpha$ ,3-dimethyl-2-oxo- $\alpha$ -[(1S)-1,2,3,4-tetrahydro-1-naphthalenyl]-, ( $\alpha$ R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 1056891-83-8 ZCAPLUS

CN 7-Quinolineacetone nitrile,  $\alpha$ -[(1R)-2,3-dihydro-1H-inden-1-yl]-1,2-dihydro- $\alpha$ ,3-dimethyl-2-oxo-, ( $\alpha$ S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 1056891-84-9 ZCAPLUS

CN 7-Quinolineacetonitrile,  $\alpha$ -[(1S)-2,3-dihydro-1H-inden-1-yl]-1,2-dihydro- $\alpha$ ,3-dimethyl-2-oxo-, ( $\alpha$ R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 1056891-85-0 ZCAPLUS


CN 7-Quinolineacetonitrile,  $\alpha$ -[(1S)-5-cyano-2,3-dihydro-1H-inden-1-yl]-1,2-dihydro- $\alpha$ ,3-dimethyl-2-oxo-, ( $\alpha$ R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 1056891-86-1 ZCAPLUS

CN 7-Quinolineacetonitrile,  $\alpha$ ,3-diethyl- $\alpha$ -(6-fluoro-2,3-dihydro-1H-inden-1-yl)-1,2-dihydro-2-oxo- (CA INDEX NAME)




RN 1056891-87-2 ZCAPLUS

CN 7-Quinolineacetonitrile,  $\alpha$ -(4-cyano-2,3-dihydro-1H-inden-1-yl)-1,2-dihydro- $\alpha$ ,3-dimethyl-2-oxo- (CA INDEX NAME)




RN 1056891-88-3 ZCAPLUS  
 CN 7-Quinolineacetonitrile, 1,2-dihydro- $\alpha$ ,3-dimethyl-2-oxo- $\alpha$ -  
 [(1R)-1,2,3,4-tetrahydro-1-naphthalenyl]-, ( $\alpha$ S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 1056891-89-4 ZCAPLUS  
 CN 7-Quinolineacetonitrile, 1,2-dihydro- $\alpha$ ,3-dimethyl-2-oxo- $\alpha$ -  
 [(1S)-1,2,3,4-tetrahydro-1-naphthalenyl]-, ( $\alpha$ S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 1056891-90-7 ZCAPLUS  
 CN 7-Quinolineacetonitrile,  $\alpha$ -[(1R)-2,3-dihydro-1H-inden-1-yl]-1,2-  
 dihydro- $\alpha$ ,3-dimethyl-2-oxo-, ( $\alpha$ R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 1056891-91-8 ZCAPLUS


CN 7-Quinolineacetonitrile,  $\alpha$ -(6,7-dihydro-5H-cyclopenta[b]pyridin-7-yl)-1,2-dihydro- $\alpha$ ,3-dimethyl-2-oxo-, ( $\alpha$ R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 1056891-93-0 ZCAPLUS


CN 7-Quinolineacetonitrile,  $\alpha$ -(2,3-dihydro-1H-inden-1-yl)-1,2-dihydro- $\alpha$ ,3-dimethyl-2-oxo- (CA INDEX NAME)



RN 1056891-94-1 ZCAPLUS

CN 7-Quinolineacetonitrile,  $\alpha$ -[(4R)-3,4-dihydro-2H-1-benzopyran-4-yl]-3-ethyl-1,2-dihydro- $\alpha$ -methyl-2-oxo-, ( $\alpha$ R)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 1056891-95-2 ZCAPLUS


CN 7-Quinolineacetonitrile,  $\alpha$ -[(4R)-3,4-dihydro-2H-1-benzopyran-4-yl]-3-ethyl-1,2-dihydro- $\alpha$ -methyl-2-oxo-, ( $\alpha$ S)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 1056891-99-6 ZCAPLUS


CN 7-Quinolineacetone nitrile,  $\alpha$ -(2,3-dihydro-6-methoxy-1H-inden-1-yl)-  
 $\alpha$ ,3-diethyl-1,2-dihydro-2-oxo- (CA INDEX NAME)



RN 1056892-00-2 ZCAPLUS

CN 7-Quinolineacetone nitrile,  $\alpha$ -[(1R)-6-bromo-2,3-dihydro-1H-inden-1-yl]-  
 1,2-dihydro- $\alpha$ ,3-dimethyl-2-oxo-, ( $\alpha$ S)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 1056892-01-3 ZCAPLUS


CN 7-Quinolineacetone nitrile,  $\alpha$ -[(1R)-6-bromo-2,3-dihydro-1H-inden-1-yl]-  
 1,2-dihydro- $\alpha$ ,3-dimethyl-2-oxo-, ( $\alpha$ R)-rel- (CA INDEX NAME)

Relative stereochemistry.




RN 1056892-05-7 ZCAPLUS


CN 7-Quinolineacetone nitrile, 1,2-dihydro- $\alpha$ ,3-dimethyl-2-oxo- $\alpha$ -  
 (1,2,3,4-tetrahydro-1-naphthalenyl)- (CA INDEX NAME)




IT 1056887-62-7P 1056887-63-8P 1056887-65-0P  
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU  
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES  
 (Uses)  
 (preparation of quinoline derivs. as PARP and TANK inhibitors useful in the  
 treatment of diseases)  
 RN 1056887-62-7 ZCAPLUS  
 CN 7-Quinolineacetonitrile, α-(4-cyanophenyl)-3-ethyl-1,2-dihydro-2-oxo-  
 α-(phenylmethyl)- (CA INDEX NAME)



RN 1056887-63-8 ZCAPLUS  
 CN 7-Quinolineacetonitrile, 3-ethyl-1,2-dihydro-2-oxo-α-phenyl-  
 (phenylmethyl)- (CA INDEX NAME)



RN 1056887-65-0 ZCAPLUS  
 CN 7-Quinolineacetonitrile, α-cyclopropyl-3-ethyl-1,2-dihydro-2-oxo-  
 α-(phenylmethyl)- (CA INDEX NAME)






REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 6 OF 10 ZCAPLUS COPYRIGHT 2009 ACS on STN  
 ACCESSION NUMBER: 2005:523429 ZCAPLUS <<LOGINID::20090907>>  
 DOCUMENT NUMBER: 143:60002  
 TITLE: Preparation of 7-phenylalkyl substituted  
 2-quinolinones and 2-quinoxalinones as  
 poly(ADP-ribose) polymerase inhibitors  
 INVENTOR(S): Mabire, Dominique Jean-pierre; Guillemont, Jerome  
 Emile Georges; Van Dun, Jacobus Alphonsus Josephus;  
 Somers, Maria Victorina Francisca; Wouters, Walter  
 Boudewijn Leopold  
 PATENT ASSIGNEE(S): Janssen Pharmaceutica N. V., Belg.  
 SOURCE: PCT Int. Appl., 55 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005054209	A1	20050616	WO 2004-EP13162	20041118
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004295057	A1	20050616	AU 2004-295057	20041118
CA 2546002	A1	20050616	CA 2004-2546002	20041118
EP 1709011	A1	20061011	EP 2004-819600	20041118
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR, IS, YU				
CN 1882549	A	20061220	CN 2004-80034287	20041118
BR 2004016817	A	20070306	BR 2004-16817	20041118
JP 2007513087	T	20070524	JP 2006-540337	20041118
SG 150534	A1	20090330	SG 2009-1198	20041118
US 20080249099	A1	20081009	US 2006-595882	20060517
IN 2006DN02810	A	20070803	IN 2006-DN2810	20060518
MX 2006005686	A	20060817	MX 2006-5686	20060519
ZA 2006004076	A	20070926	ZA 2006-4076	20060519
KR 2006111532	A	20061027	KR 2006-710200	20060525
NO 2006002892	A	20060809	NO 2006-2892	20060620
PRIORITY APPLN. INFO.:			EP 2003-78650	A 20031120
			WO 2004-EP13162	W 20041118
OTHER SOURCE(S):		CASREACT 143:60002; MARPAT 143:60002		
IT 854397-87-8P				
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)				
(preparation of 7-phenylalkyl substituted 2-quinolinones and 2-quinoxalinones as poly(ADP-ribose) polymerase inhibitors)				
RN 854397-87-8 ZCAPLUS				

CN 2(1H)-Quinoxalinone, 3-ethyl-7-(hydroxyphenylmethyl)- (CA INDEX NAME)




IT 130347-24-9P 854397-78-7P 854397-82-3P  
854397-84-5P 854397-90-3P 854397-92-5P  
854397-94-7P 854398-00-8P 854398-02-0P  
854398-05-3P 854398-09-7P 854398-13-3P  
854398-17-7P 854398-21-3P 854398-25-7P  
854398-28-0P 854398-32-6P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of 7-phenylalkyl substituted 2-quinolinones and 2-quinoxalinones as poly(ADP-ribose) polymerase inhibitors)


RN 130347-24-9 ZCAPLUS

CN 2(1H)-Quinoxalinone, 7-[1H-imidazol-1-yl[4-(1-methylethyl)phenyl]methyl]-3-methyl- (CA INDEX NAME)



RN 854397-78-7 ZCAPLUS

CN 2(1H)-Quinoxalinone, 3-ethyl-7-[2-(1H-imidazol-1-yl)-2-phenylethyl]- (CA INDEX NAME)




RN 854397-82-3 ZCAPLUS

CN 2(1H)-Quinoxalinone, 3-ethyl-7-[[4-[(2-methoxyethyl)amino]-1-piperidinyl]phenylmethyl]-, ethanedioate (1:1) (CA INDEX NAME)

CM 1

CRN 854397-81-2

CMF C25 H32 N4 O2



CM 2


CRN 144-62-7

CMF C2 H2 O4




RN 854397-84-5 ZCAPLUS

CN 2 (1H)-Quinoxalinone, 7-[3-(dimethylamino)-1-phenylpropyl]-3-methyl- (CA INDEX NAME)




RN 854397-90-3 ZCAPLUS

CN 2 (1H)-Quinoxalinone, 7-[(4-chlorophenyl)-1-piperidinylmethyl]-3-ethyl- (CA INDEX NAME)




RN 854397-92-5 ZCAPLUS

CN 4-Piperidinecarboxylic acid, 1-[(4-chlorophenyl)(2-ethyl-3,4-dihydro-3-oxo-6-quinoxaliny)lmethyl]-, ethyl ester (CA INDEX NAME)




RN 854397-94-7 ZCAPLUS  
 CN 2(1H)-Quinoxalinone, 7-[2-(4-chlorophenyl)-2-(1-pyrrolidinyl)ethyl]-3-ethyl- (CA INDEX NAME)



RN 854398-00-8 ZCAPLUS  
 CN 2(1H)-Quinoxalinone, 3-ethyl-7-[[[3-[methyl(phenylmethyl)amino]propyl]amino]phenylmethyl]-, ethanedioate (1:1) (CA INDEX NAME)

CM 1

CRN 854397-99-2  
 CMF C28 H32 N4 O




CM 2

CRN 144-62-7  
 CMF C2 H2 O4




RN 854398-02-0 ZCAPLUS

CN 2(1H)-Quinoxalinone, 7-[2-(4-chlorophenyl)-2-hydroxyethyl]-3-ethyl- (CA INDEX NAME)




RN 854398-05-3 ZCAPLUS

CN 2(1H)-Quinoxalinone, 3-ethyl-7-(2-hydroxy-2-phenylethyl)- (CA INDEX NAME)




RN 854398-09-7 ZCAPLUS

CN 2(1H)-Quinoxalinone, 3-ethyl-7-[(3-fluorophenyl)-1H-imidazol-1-ylmethyl]- (CA INDEX NAME)




RN 854398-13-3 ZCAPLUS


CN 2(1H)-Quinoxalinone, 3-ethyl-7-[(2-fluorophenyl)-1H-imidazol-1-ylmethyl]- (CA INDEX NAME)




RN 854398-17-7 ZCAPLUS  
 CN 2(1H)-Quinoxalinone, 3-ethyl-7-(phenyl-1H-pyrazol-1-ylmethyl)- (CA INDEX NAME)




RN 854398-21-3 ZCAPLUS  
 CN 2(1H)-Quinoxalinone, 7-[2-(4-chlorophenyl)-2-(1H-imidazol-1-yl)ethyl]-3-ethyl- (CA INDEX NAME)



RN 854398-25-7 ZCAPLUS  
 CN 2(1H)-Quinoxalinone, 3-ethyl-7-(phenyl-3-pyridinylmethyl)- (CA INDEX NAME)




RN 854398-28-0 ZCAPLUS  
 CN 2(1H)-Quinoxalinone, 3-ethyl-7-(phenyl-1H-1,2,4-triazol-1-ylmethyl)- (CA INDEX NAME)



RN 854398-32-6 ZCAPLUS

CN 2(1H)-Quinoxalinone, 3-ethyl-7-[(4-fluorophenyl)-1H-imidazol-1-ylmethyl]-  
(CA INDEX NAME)




IT 130346-67-7 130346-70-2

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL  
(Biological study); USES (Uses)

(preparation of 7-phenylalkyl substituted 2-quinolinones and  
2-quinoxalinones as poly(ADP-ribose) polymerase inhibitors)


RN 130346-67-7 ZCAPLUS

CN 2(1H)-Quinoxalinone, 7-[(4-chlorophenyl)-1H-imidazol-1-ylmethyl]-3-methyl-  
(CA INDEX NAME)




RN 130346-70-2 ZCAPLUS


CN 2(1H)-Quinoxalinone, 3-ethyl-7-(1H-imidazol-1-ylphenylmethyl)- (CA INDEX  
NAME)




IT 854398-62-2P 854398-71-3P 854398-92-8P  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
 (Reactant or reagent)  
 (preparation of 7-phenylalkyl substituted 2-quinolinones and  
 2-quinoxalinones as poly(ADP-ribose) polymerase inhibitors)  
 RN 854398-62-2 ZCAPLUS  
 CN 2(1H)-Quinoxalinone, 7-benzoyl-3-ethyl- (CA INDEX NAME)



RN 854398-71-3 ZCAPLUS  
 CN 2(1H)-Quinoxalinone, 3-ethyl-7-[(methylsulfonyl)oxy]phenylmethyl- (CA  
 INDEX NAME)



RN 854398-92-8 ZCAPLUS  
 CN 2(1H)-Quinolinone, 7-[3-(dimethylamino)-1-phenyl-1-propen-1-yl]-3-methyl-  
 (CA INDEX NAME)



OS.CITING REF COUNT: 2 THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD  
 (2 CITINGS)  
 REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS  
 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


L8 ANSWER 7 OF 10 ZCAPLUS COPYRIGHT 2009 ACS on STN  
 ACCESSION NUMBER: 2005:523424 ZCAPLUS <<LOGINID::20090907>>  
 DOCUMENT NUMBER: 143:60001  
 TITLE: Preparation of 6-alkenyl and 6-phenylalkyl substituted  
 2-quinolinones and 2-quinoxalinones as  
 poly(ADP-ribose) polymerase inhibitors  
 INVENTOR(S): Mabire, Dominique Jean-pierre; Guillemont, Jerome



Emile Georges; Van Dun, Jacobus Alphonsus Josephus;  
 Somers, Maria Victorina Francisca; Wouters, Walter  
 Boudewijn Leopold  
 PATENT ASSIGNEE(S): Janssen Pharmaceutica N. V., Belg.  
 SOURCE: PCT Int. Appl., 102 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005054201	A1	20050616	WO 2004-EP13163	20041118
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
AU 2004295058	A1	20050616	AU 2004-295058	20041118
CA 2546300	A1	20050616	CA 2004-2546300	20041118
EP 1687277	A1	20060809	EP 2004-819601	20041118
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, IS			
CN 1882547	A	20061220	CN 2004-80034176	20041118
BR 2004016206	A	20061226	BR 2004-16206	20041118
JP 2007511574	T	20070510	JP 2006-540338	20041118
SG 150533	A1	20090330	SG 2009-1197	20041118
US 20070072842	A1	20070329	US 2006-595891	20060518
IN 2006DN02813	A	20070803	IN 2006-DN2813	20060518
MX 2006005687	A	20060817	MX 2006-5687	20060519
ZA 2006004075	A	20070926	ZA 2006-4075	20060519
KR 2006115393	A	20061108	KR 2006-710201	20060525
NO 2006002894	A	20060809	NO 2006-2894	20060620
PRIORITY APPLN. INFO.:			WO 2003-EP13028	A 20031120
			EP 2003-78860	A 20031205
			WO 2003-EP130	A 20031120
			WO 2004-EP13163	W 20041118

OTHER SOURCE(S): CASREACT 143:60001; MARPAT 143:60001  
 IT 854534-70-6P  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
 (preparation of 6-alkenyl and 6-phenylalkyl substituted 2-quinolinones and 2-quinoxalinones as poly(ADP-ribose) polymerase inhibitors)  
 RN 854534-70-6 ZCAPLUS  
 CN 2(1H)-Quinoxalinone, 7-[2-(4-chlorophenyl)-2-oxoethyl]-3-ethyl- (CA INDEX NAME)



OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD  
(1 CITINGS)  
REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS  
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


L8 ANSWER 8 OF 10 ZCAPLUS COPYRIGHT 2009 ACS on STN  
ACCESSION NUMBER: 2000:527827 ZCAPLUS <<LOGINID::20090907>>  
DOCUMENT NUMBER: 134:162992  
TITLE: Synthesis and antimicrobial activities of some novel  
quinoxalinone derivatives  
AUTHOR(S): Ali, M. M.; Ismail, M. M. F.; El-Gaby, M. S. A.;  
Zahran, M. A.; Ammar, Y. A.  
CORPORATE SOURCE: Dep. of Chemistry, Faculty of Science, Al-Azhar Univ.,  
Cairo, 11884, Egypt  
SOURCE: Molecules [online computer file] (2000), 5(6), 864-873  
CODEN: MOLEFW; ISSN: 1420-3049  
URL: <http://www.mdpi.org/molecules/papers/50600864.pdf>  
PUBLISHER: Molecular Diversity Preservation International  
DOCUMENT TYPE: Journal; (online computer file)  
LANGUAGE: English  
OTHER SOURCE(S): CASREACT 134:162992  
IT 325469-52-1P  
RL: BAC (Biological activity or effector, except adverse); BSU (Biological  
study, unclassified); RCT (Reactant); SPN (Synthetic preparation); BIOL  
(Biological study); PREP (Preparation); RACT (Reactant or reagent)  
(preparation and antimicrobial activities of quinoxalinone derivs.)  
RN 325469-52-1 ZCAPLUS  
CN 2(1H)-Quinoxalinone, 7-benzoyl-3-methyl- (CA INDEX NAME)



OS.CITING REF COUNT: 35 THERE ARE 35 CAPLUS RECORDS THAT CITE THIS  
RECORD (35 CITINGS)  
REFERENCE COUNT: 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS  
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 9 OF 10 ZCAPLUS COPYRIGHT 2009 ACS on STN  
ACCESSION NUMBER: 1992:592207 ZCAPLUS <<LOGINID::20090907>>  
DOCUMENT NUMBER: 117:192207  
ORIGINAL REFERENCE NO.: 117:33223a, 33226a  
TITLE: Fluorine-19 NMR studies on the mechanism of riboflavin  
synthase. Synthesis of  
6-(trifluoromethyl)-7-oxo-8-(D-ribityl)lumazine and  
6-(trifluoromethyl)-7-methyl-8-(D-ribityl)lumazine  
AUTHOR(S): Cushman, Mark; Patel, Hemantkumar H.; Scheuring,  
Johannes; Bacher, Adelbert  
CORPORATE SOURCE: Sch. Pharm. Pharm. Sci., Purdue Univ., West Lafayette,  
IN, 47907, USA  
SOURCE: Journal of Organic Chemistry (1992), 57(21), 5630-43  
CODEN: JOCEAH; ISSN: 0022-3263  
DOCUMENT TYPE: Journal

LANGUAGE: English  
IT 143309-80-2P  
RL: SPN (Synthetic preparation); PREP (Preparation)  
(preparation of)  
RN 143309-80-2 ZCAPLUS  
CN 2(1H)-Quinoxalinone, 7-benzoyl-3-(trifluoromethyl)- (CA INDEX NAME)



OS.CITING REF COUNT: 31 THERE ARE 31 CAPLUS RECORDS THAT CITE THIS  
RECORD (31 CITINGS)